1. Home
  2. ATHA vs GDHG Comparison

ATHA vs GDHG Comparison

Compare ATHA & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • GDHG
  • Stock Information
  • Founded
  • ATHA 2011
  • GDHG 2008
  • Country
  • ATHA United States
  • GDHG China
  • Employees
  • ATHA N/A
  • GDHG N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • GDHG Services-Misc. Amusement & Recreation
  • Sector
  • ATHA Health Care
  • GDHG Consumer Discretionary
  • Exchange
  • ATHA Nasdaq
  • GDHG Nasdaq
  • Market Cap
  • ATHA 18.2M
  • GDHG 19.4M
  • IPO Year
  • ATHA 2020
  • GDHG 2023
  • Fundamental
  • Price
  • ATHA $4.72
  • GDHG $4.55
  • Analyst Decision
  • ATHA
  • GDHG
  • Analyst Count
  • ATHA 0
  • GDHG 0
  • Target Price
  • ATHA N/A
  • GDHG N/A
  • AVG Volume (30 Days)
  • ATHA 25.6K
  • GDHG 22.0K
  • Earning Date
  • ATHA 11-06-2025
  • GDHG 07-11-2025
  • Dividend Yield
  • ATHA N/A
  • GDHG N/A
  • EPS Growth
  • ATHA N/A
  • GDHG N/A
  • EPS
  • ATHA N/A
  • GDHG N/A
  • Revenue
  • ATHA N/A
  • GDHG $16,666,899.00
  • Revenue This Year
  • ATHA N/A
  • GDHG N/A
  • Revenue Next Year
  • ATHA N/A
  • GDHG N/A
  • P/E Ratio
  • ATHA N/A
  • GDHG N/A
  • Revenue Growth
  • ATHA N/A
  • GDHG N/A
  • 52 Week Low
  • ATHA $2.20
  • GDHG $2.40
  • 52 Week High
  • ATHA $6.79
  • GDHG $1,968.41
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 61.31
  • GDHG 37.83
  • Support Level
  • ATHA $4.31
  • GDHG $3.94
  • Resistance Level
  • ATHA $4.95
  • GDHG $4.89
  • Average True Range (ATR)
  • ATHA 0.37
  • GDHG 0.49
  • MACD
  • ATHA -0.04
  • GDHG 0.10
  • Stochastic Oscillator
  • ATHA 73.60
  • GDHG 34.44

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.

Share on Social Networks: